Northstar Asset Management LLC decreased its position in Zoetis Inc. (NYSE:ZTS) by 1.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,652 shares of the company’s stock after selling 878 shares during the period. Zoetis comprises about 1.8% of Northstar Asset Management LLC’s portfolio, making the stock its 13th largest position. Northstar Asset Management LLC’s holdings in Zoetis were worth $4,095,000 as of its most recent filing with the SEC.
Other institutional investors have also recently modified their holdings of the company. Guardian Life Insurance Co. of America increased its position in shares of Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock worth $102,000 after buying an additional 13 shares during the last quarter. Assetmark Inc. increased its position in shares of Zoetis by 4.6% in the first quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock worth $102,000 after buying an additional 85 shares during the last quarter. Point72 Asia Hong Kong Ltd purchased a new position in shares of Zoetis during the first quarter worth approximately $111,000. Advisory Services Network LLC bought a new stake in shares of Zoetis during the first quarter worth $112,000. Finally, First Interstate Bank boosted its stake in shares of Zoetis by 3.5% in the first quarter. First Interstate Bank now owns 2,250 shares of the company’s stock worth $120,000 after buying an additional 76 shares during the period. Hedge funds and other institutional investors own 92.70% of the company’s stock.
Zoetis Inc. (ZTS) traded down 0.25% during mid-day trading on Friday, hitting $60.75. 1,513,092 shares of the stock traded hands. The firm has a market cap of $29.71 billion, a PE ratio of 34.34 and a beta of 1.02. The stock has a 50 day moving average price of $61.95 and a 200 day moving average price of $58.24. Zoetis Inc. has a 12-month low of $46.86 and a 12-month high of $63.85.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.com-unik.info/2017/08/19/zoetis-inc-zts-position-decreased-by-northstar-asset-management-llc-updated-updated-updated.html.
A number of brokerages recently weighed in on ZTS. Cowen and Company set a $70.00 price target on shares of Zoetis and gave the company a “buy” rating in a research report on Monday, July 17th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $65.00 target price (up from $62.00) on shares of Zoetis in a report on Monday, July 17th. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $71.00 target price for the company in a report on Tuesday, June 20th. Hilliard Lyons began coverage on shares of Zoetis in a report on Tuesday, June 20th. They issued a “buy” rating and a $77.00 target price for the company. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $65.00 target price on shares of Zoetis in a report on Friday, July 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $64.78.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
What are top analysts saying about Zoetis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zoetis Inc. and related companies.